Lipocine, Inc. Stock price
Is Lipocine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Lipocine, Inc. Stock Analysis
Analyst Opinions
8 Analysts have issued a Lipocine, Inc. forecast:
Analyst Opinions
8 Analysts have issued a Lipocine, Inc. forecast:
Don't miss a Thing! We will send you all news about Lipocine, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lipocine, Inc. Stock News
Company Profile
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.
| Head office | United States |
| CEO | Dr. Patel |
| Employees | 14 |
| Founded | 2011 |
| Website | www.lipocine.com |


